| Literature DB >> 28972073 |
Maria De Grandis1, Florence Bardin1, Cyril Fauriat1, Christophe Zemmour2, Abdessamad El-Kaoutari1, Arnauld Sergé1, Samuel Granjeaud1, Laurent Pouyet1, Camille Montersino1, Anne-Sophie Chretien1, Marie-Joelle Mozziconacci3, Remy Castellano1, Ghislain Bidaut1, Jean-Marie Boher2,4, Yves Collette1, Stéphane J C Mancini1, Norbert Vey1,5, Michel Aurrand-Lions6.
Abstract
Acute myeloid leukemia (AML) originates from hematopoietic stem and progenitor cells that acquire somatic mutations, leading to disease and clonogenic evolution. AML is characterized by accumulation of immature myeloid cells in the bone marrow and phenotypic cellular heterogeneity reflective of normal hematopoietic differentiation. Here, we show that JAM-C expression defines a subset of leukemic cells endowed with leukemia-initiating cell activity (LIC). Stratification of de novo AML patients at diagnosis based on JAM-C-expressing cells frequencies in the blood served as an independent prognostic marker for disease outcome. Using publicly available leukemic stem cell (LSC) gene expression profiles and gene expression data generated from JAM-C-expressing leukemic cells, we defined a single cell core gene expression signature correlated to JAM-C expression that reveals LSC heterogeneity. Finally, we demonstrated that JAM-C controls Src family kinase (SFK) activation in LSC and that LIC with exacerbated SFK activation was uniquely found within the JAM-C-expressing LSC compartment. Cancer Res; 77(23); 6627-40. ©2017 AACR. ©2017 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28972073 DOI: 10.1158/0008-5472.CAN-17-1223
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701